The protein encoded by this gene is a member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells of the prostate gland and secreted into the seminal plasma. This protein has inhibin-like activity. It may have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. The expression of the encoded protein is found to be decreased in prostate cancer. Two alternatively spliced transcript variants encoding different isoforms are described for this gene. The use of alternate polyadenylation sites has been found for this gene. [provided by RefSeq, Jul 2008].
Bergström, Järemo, Nilsson, Adamo, Bergh: "Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness." in: The Prostate, Vol. 78, Issue 4, pp. 257-265, (2019) (PubMed).
Debiais-Delpech, Godet, Pedretti, Bernard, Irani, Cathelineau, Cussenot, Fromont: "Expression patterns of candidate susceptibility genes HNF1? and CtBP2 in prostate cancer: association with tumor progression." in: Urologic oncology, Vol. 32, Issue 4, pp. 426-32, (2014) (PubMed).
Kälin, Cima, Schiess, Fankhauser, Powles, Wild, Templeton, Cerny, Aebersold, Krek, Gillessen: "Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome." in: European urology, Vol. 60, Issue 6, pp. 1235-43, (2011) (PubMed).